Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fenretinide

Next Previous
X
Search
Drug Profile

Fenretinide

Alternative Names: 4 HPR; HPR; MCNR 1967; RT-101; ST-602

Latest Information Update: 25 Sep 2021

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ortho-McNeil
  • Developer Ortho-McNeil; ReVision Therapeutics
  • Class Antifibrotics; Antineoplastics; Antivirals; Chemopreventatives; Retinoids; Small molecules
  • Mechanism of Action Plasma retinol-binding protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Basal cell cancer; Bladder cancer; Breast cancer; Dry age-related macular degeneration; Glioma; Neuroblastoma; Prostate cancer; Rheumatoid arthritis

Most Recent Events

  • 23 Jan 2015 Discontinued - Phase-II for Dry age-related macular degeneration in USA (PO)
  • 18 Oct 2010 Final efficacy data from a phase IIb trial in Age-related macular degeneration released by ReVision Therapeutics
  • 15 Apr 2009 Fenretinide received Fast Track designation for Age-related macular degeneration [PO] in USA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top